Bristol-Myers and Celgene enter agreement to evaluate mmunotherapy and chemotherapy combo
Bristol-Myers and Celgene announced a clinical trial collaboration to evaluate safety, tolerability and preliminary efficacy of a combination regimen of Bristol-Myers’ PD-1 immune checkpoint inhibitor, OPDIVO (nivolumab), and Celgene’s nab® technology-based chemotherapy ABRAXANE® in a Phase I study. August 20, 2014